Medicines Discovery Catapult will conduct an in vivo 18F imaging and toxicity study.
UNIVERSITY OF NOTTINGHAM (THE)contractContracts Finder ↗Ref Medicines Discovery Catapult.SME suitablecomplete
Estimated value
£77k
Awarded value
£77k
Awarded 04 May 2022
Suppliers
1
Lots
1
1 awarded
Published
07 Jul 2022
Deadline 04 May 2022
Description
The Medicines Discovery Catapult will conduct an in vivo 18F imaging and toxicity study in naive and cancer xenograft bearing mice of our HER2 targeting apoferritin anti-cancer drug delivery platform.
Scope
- Reference
- Medicines Discovery Catapult.
- Total value
- £76,535.54 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 04 May 2022 to 04 May 2022
- CPV classifications
- 73100000
- Particular suitability
- Small and medium-sized enterprises (SME)
Submission & procedure
- Submission deadline
- 04 May 2022, 6:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£77k
Award date
04 May 2022
Contract start
04 May 2022
Contract end
04 May 2022
Awarded to
Awarded suppliers· 1 supplier
Awarded 04 May 2022 · Contract period 04 May 2022 — 04 May 2022
Award value
£77k
Other contracts from UNIVERSITY OF NOTTINGHAM (THE)
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to MEDICINES DISCOVERY CATAPULT SERVICES LIMITED· 5
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| PS26036 - Analysis for Innovators Critical Enabler Partnership | contract | — | 23 Feb 2026 |
| MDCS - Winter Capacity (21/22) | call off | £127.8m | 13 Apr 2023 |
| Winter Surge Capacity (21/22) | call off | £59.3m | 29 Nov 2022 |
| National Microbiology Framework - Lot 4 Clinical Laboratory Diagnostic Testing Services | call off | £294.1m | 19 Apr 2021 |
| National Microbiology Framework - Lot 4: Clinical Laboratory Diagnostic Testing Services | contract | — | 18 Apr 2021 |